|
KMID : 0941820100200030268
|
|
Korean Journal of Clinical Pharmacy
2010 Volume.20 No. 3 p.268 ~ p.277
|
|
|
Economic Evaluation of Ramosetron in Male Patients with Diarrhea-predominant Irritable Bowel Syndrome in Korea
|
|
Sohn Hyun-Soon
Lee Tae-Jin
Kim Sun
|
|
|
Abstract
|
|
|
This study was conducted to analyze the cost-utility of ramosetron monotherapy, trimebutine monotherapy and trimebutine+ loperamide combination therapy in male diarrhea-predominant patients with irritable bowel syndrome (IBS) in Korean healthcare setting. We constructed a decision-analytical model to estimate both total costs for each state of health and outcomes such as IBS-symptoms improvement for 3 and 6 months time horizon. Base analysis found that
for ramosetron treatment with the price of KW910 for 5 μg tablet, incremental cost effectiveness ratios (ICERs, cost per quality-adjusted life day) were KW85,000 and KW62,000 for 3 months and 6 months, respectively, compared with trimebutine. But ramosetron was a dominant strategy when compared with trimebutine+loperamide for both 3 months and 6 months. Sensitivity analyses showed robust results for drug acquisition costs till ramosetron price of KW950/tablet. In
conclusion, ramosetron was a cost-effective regimen compared with trimebutine or rimebutine+loperamide from the societal perspective.
|
|
|
KEYWORD
|
|
|
cost-utility, irritable bowel syndrome, ramosetron, trimebutine, loperamide
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|